GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

Meredith Buxton,Brian M. Alexander,Donald A. Berry,Webster K. Cavenee,Howard Colman,John Frederick de Groot,Benjamin M. Ellingson,Gary B. Gordon,Mustafa Khasraw,Andrew B. Lassman,Wenbin Li,Michael Lim,Ingo K. Mellinghoff,James R. Perry,Erik P. Sulman,Kirk Tanner,Michael Weller,Patrick Y. Wen,W. K. Alfred Yung,Timothy F. Cloughesy,Gbm Agile Investigators

GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

2020

TPS2579Background: Glioblastoma (GBM) is an aggressive brain tumor with few effective therapies and is invariably fatal. Developing new therapies for patients with GBM requires focused interaction ...

Keywords:

Oncology
recurrent glioblastoma
Internal medicine
Pathology
newly diagnosed
Medicine
Agile software development
Glioblastoma
Brain tumor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations